After repeated failures in previous research, a new study suggests hydroxychloroquine can improve survival odds for some coronavirus patients.
Hospitalized coronavirus patients given hydroxychloroquine were 50 percent less likely to die of the brutal infection than those who did not receive the drug in a Henry Ford Health System study of 2,541 people.
It comes after several large-scale studies found no benefit to the malaria drug, touted by Trump, which prompted the US Food and Drug Administration (FDA) to revoke its emergency use authorization for the drug.
The Henry Ford team puts their better results down to timing and selectivity. They gave coronavirus patients hydroxychloroquine earlier on in the course of their illnesses, and only if they were not at high risk for heart problems.
But critics say that these same choices that helped Henry Ford get better results from hydroxychloroquine also make the research less convincing, and noted that more of the hydroxychloroquine group was also treated with steroids, which data suggests combats dangerous inflammation in coronavirus patients.